- Home
- NSLR vs PROF Comparison
NSLR vs PROF Comparison
Compare NSLR & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSLR | PROF |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.4M | 263.8M |
| IPO Year | 2011 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NSLR | PROF |
|---|---|---|
| Price | $10.21 | $7.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 299.2K | 107.3K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | N/A | $92.40 |
| Revenue Next Year | N/A | $64.10 |
| P/E Ratio | ★ N/A | $38.58 |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $9.88 | $3.92 |
| 52 Week High | $12.19 | $8.95 |
Technical Indicators
Market Signals| Indicator | NSLR | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 34.58 | 56.28 |
| Support Level | N/A | $6.43 |
| Resistance Level | $11.62 | $7.93 |
| Average True Range (ATR) | 0.55 | 0.42 |
| MACD | -0.10 | 0.02 |
| Stochastic Oscillator | 16.41 | 46.40 |
Price Performance
Historical ComparisonAbout PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.